Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases, including new first-in-class alternatives to steroids.
Novel experimental treatments for immune and inflammatory diseases.
Countering Dysfunctional Immune Responses
Our novel monoclonal antibodies suppress certain immune signaling proteins, including Toll-like Receptor 4 (TLR4), which is associated with a broad range of acute and chronic diseases.
Acute Respiratory Distress Syndrome
We have prioritized the study of our first-in-class monoclonal antibody in patients with Acute Respiratory Distress Syndrome. This life-threatening for of lung injury is the result of an overactive and dysfunctional innate immune response, sometimes described as a “cytokine storm.” Our product candidate is designed to inhibit this cytokine storm and the inflammation, fluid accumulation and lung injury it causes.
Inhibiting the Inflammation Cascade
Allergic Contact Dermatitis
Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. In two clinical studies, this topical therapy has demonstrated significant improvement of multiple symptoms in contact dermatitis patients. Edesa also intends to expand the utility of our sPLA2 inhibitor technology across multiple indications.